#Japan #Healthcare AI #Callisto #Shinjuku #Tauns

Strategic Partnership Between Callisto and Tauns

In a significant move aimed at advancing the medical data infrastructure and AI capabilities, Callisto, a Tokyo-based startup specializing in medical imaging data for AI and clinical research, has entered into a strategic partnership with Tauns, a leading in-vitro diagnostic manufacturer based in Izu, Shizuoka. This collaboration is set to combine Callisto's technical expertise and medical data resources with Tauns’ robust network of healthcare institutions and pharmaceutical commercialization capabilities.

Background of the Collaboration

The proper integration and utilization of diverse medical data—including radiological images, pathology images, electronic health records, and molecular data—are paramount for enhancing research and development in medical AI and drug discovery. As such, the collaboration aims to construct a comprehensive multi-modal medical data platform while ensuring compliance with relevant laws and maintaining high standards of ethical and informational security.

Callisto has previously focused on building and providing medical imaging datasets in collaboration with domestic healthcare institutions, while offering contract development services and technical consulting for drugs and healthcare AI. Tauns, known for its established network in the realm of in-vitro diagnostics, brings with it substantial experience in specimen collection, regulatory affairs, and distribution strategies, making it an invaluable partner for this initiative.

Objectives of the Partnership

Building a Multi-Modal Medical Data Platform

The collaboration seeks to establish a versatile medical data infrastructure that effectively integrates clinical information from medical imaging, electronic health records, specimen data, and biobank samples. This integrated approach will streamline the availability of medical data for research and development purposes.

Establishing an AI Utilization Platform

In addition to the data infrastructure, the partnership will develop operational environments including computational resources, AI models, and analytical setups that support the advanced utilization of medical data, continuously generating valuable insights for healthcare applications.

Accelerating Expansion in Pharmaceuticals and International Markets

By leveraging both companies' customer bases and commercialization expertise, the partnership aims to enhance drug development processes and accelerate international expansion efforts. Strengthening business development, marketing, and recruitment will be critical to drive this new strategic direction.

Comments from Leadership

Masanori Nonaka, President of Tauns, expressed enthusiasm about the partnership, stating, "We are delighted to collaborate with Callisto in unlocking the value of medical data for healthcare solutions through this partnership. Their high level of expertise in acquiring, processing, and analyzing medical data positions them as a crucial partner in our endeavor."

Meanwhile, Charis Han, CEO of Callisto, remarked on the importance of their technology and data assets in supporting the infrastructure for medical AI and drug discovery. Han stated, "We are grateful for the trust and investment from Tauns as we aim to combine our resources to speed up our expansion in the pharmaceutical industry and abroad."

Looking Forward

Japan, recognized as one of the leading aging societies with a universal healthcare system, hosts a wealth of high-quality and diverse medical data that includes substantial amounts of radiological and clinical information. Callisto has previously provided datasets to around 20 pharmaceutical companies, medical device manufacturers, and medical AI entities across Japan, the U.S., Europe, and South Korea, derived from collaborations with domestic healthcare institutions.

Through this partnership, Callisto and Tauns aspire to create a large-scale, multi-modal medical data infrastructure and AI analysis platform that supports more accurate and timely diagnostics, cost-efficiency in healthcare, and enhanced health longevity worldwide.

About Tauns

Tauns is a prominent manufacturer of infectious disease test kits, actively involved in the development, production, and commercialization of in vitro diagnostic drugs and research reagents. The company has established a strong foundation of trust within healthcare institutions, primarily focusing on the field of infectious disease point-of-care testing. Looking ahead, Tauns is set to expand into new areas, including the development of the medical data and AI analytical infrastructures.

Learn more about Tauns

About Callisto

Callisto is an emerging startup focused on constructing medical imaging data infrastructures aimed at healthcare AI and clinical research. Leveraging its network within Japan's healthcare institutions, Callisto integrates various types of data, including radiological images, clinical information, and molecular data. They offer a comprehensive suite of services from data extraction, anonymization, selection, standardization, and annotation to quality management, enabling applications in AI model development, external evaluations, and more.

Learn more about Callisto

Recruitment Information

The strategic capital and business partnership marks a new chapter for both companies as Callisto looks to strengthen its recruitment to support business growth. They are currently focusing on hiring various positions, including sales, VPoE, medical AI engineers, software engineers, and data set managers, inviting those passionate about shaping the future of healthcare to apply.

Visit Callisto's recruitment page

For inquiries related to data provision, dataset purchases, contract research in drug discovery/healthcare AI, or collaboration opportunities, please contact: [email protected]